The­seus goes with Tang; Onc­ter­nal tri­al pa­tient dies; Lian­Bio sells drug rights to J&J

Plus, news on the Im­munome-Atre­ca as­set deal, Cy­clo Ther­a­peu­tics’ re­verse merg­er, Nestlé buy­ing CDX-7108 from Codex­is, Onc­ter­nal, Vi­siox and more.

So long, Ap­plied Mol­e­c­u­lar Trans­port: The stock sym­bol $AMTI of­fi­cial­ly be­came his­to­ry as Cy­clo Ther­a­peu­tics com­plet­ed its re­verse merg­er and took Ap­plied Mol­e­c­u­lar Trans­port’s spot on the Nas­daq un­der the tick­er $CYTH. Ap­plied Mol­e­c­u­lar Trans­port be­gan hunt­ing for strate­gic al­ter­na­tives in late March af­ter it halt­ed all R&D ac­tiv­i­ties and laid off the bulk of its staff in the wake of a Phase II flop in ul­cer­a­tive col­i­tis. The deal with Cy­clo was an­nounced in Sep­tem­ber. The com­pa­ny will now fo­cus on a Phase III study of its re­for­mu­lat­ed drug for Nie­mann-Pick Dis­ease Type C1. — Am­ber Tong 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER